Re: Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and-18 infections

Journal of the National Cancer Institute

Volumn 104, Issue 2, 2012, Pages 163-

  Mikolajczyk, Rafael T ^a   Horn, Johannes ^a   Damm, Oliver ^b   Kaufmann, Andreas M ^c   Kretzschmar, Mirjam E E ^d,e  

^a LEIBNIZ INSTITUTE FOR PREVENTION RESEARCH AND EPIDEMIOLOGY BIPS   (Germany)

^b BIELEFELD UNIVERSITY   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS ANTIBODY; VIRUS DNA;

ANTIBODY DETECTION; ANTIBODY TITER; DISEASE DURATION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNE RESPONSE; IMMUNITY; INFECTION RISK; LETTER; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; SEXUAL INTERCOURSE;

ANTIBODIES, VIRAL; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES;

EID: 84856191714     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr517     Document Type: Letter

References (5)

1. Safaeian M, Porras C, Schiffman M, et al. Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and-18 infections. J Natl Cancer Inst. 2010;102(21):1653-1662.
2. Carter JJ, Koutsky LA, Hughes JP, et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis. 2000;181(6):1911-1919. (Pubitemid 30416152)
3. Trottier H, Mahmud S, Prado JC, et al. Type-specific duration of human papillomavirus infection: implications for human papillomavirus screening and vaccination. J Infect Dis. 2008; 197(10):1436-1447. (Pubitemid 351706468)
4. Richardson H, Kelsall G, Tellier P, et al. The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev. 2003;12(6): 485-490. (Pubitemid 36713640)
5. Fraser C, Tomassini JE, Xi L, et al. Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine. Vaccine 2007; 25(21):4324-4333. (Pubitemid 46635934)